Rapid Enterprise Platform
Overview
The Rapid Enterprise Platform is a comprehensive, AI-powered solution designed to integrate deep clinical AI into healthcare workflows, particularly for imaging-based diagnoses and interventions. It goes beyond simple detection to provide deeper insights and support more informed clinical decisions across various specialties.
The platform is built for enterprise-grade security and scalability, integrating seamlessly with existing EHR, PACS, and other clinical workflows. It offers robust data and analytics capabilities, providing visibility into performance, utilization, and impact to optimize outcomes for health systems.
RapidAI’s solutions are FDA-cleared and used in over 2,500 hospitals globally, emphasizing its reliability and compliance. It supports a wide range of users, including physicians, radiologists, care teams, hospital administrators, and IT departments, by providing tools for faster interpretation, real-time collaboration, operational oversight, and seamless integration.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Deep clinical AI for advanced insights
- Workflow integration with EHR, PACS, and other systems
- Enterprise-grade security and compliance
- Data and analytics for performance optimization
- FDA-cleared AI across multiple body regions
- Radiology's AI interface for case prioritization (Navigator Pro)
- Full suite of neurocritical assessment tools
- Complete ischemic stroke solution
- AI-driven detection and growth assessment for aneurysms
- Automated measurements for aortic assessment
Use Cases
- Ischemic stroke assessment and intervention
- Intracerebral hemorrhage (ICH) and subdural hematoma (SDH) detection
- Aneurysm detection, growth assessment, and rupture risk stratification
- Pulmonary embolism detection and severity stratification
- Aortic assessment and surveillance
- Radiology case prioritization and AI interpretation assistance
What Physicians Need to Know
Leverage the AI-enhanced imaging analysis for comprehensive cardiac and vascular assessments, especially for complex cases involving coronary artery disease, aortic pathologies, and pulmonary embolisms, to improve diagnostic precision and reduce inter-observer variability. Utilize the real-time alerts and mobile access to expedite critical decisions and coordinate care efficiently across multidisciplinary teams. The heart failure risk prediction tool, based on routine cardiac CT scans, can be a powerful asset for early identification of high-risk patients, enabling proactive management and preventative strategies. Remember that while the platform offers deep clinical insights and decision support, final clinical decisions always rest with qualified healthcare providers.
The Rapid Enterprise Platform is designed for seamless integration with existing hospital IT systems, including PACS, EHR, and worklists, to ensure a unified and efficient workflow. It offers a vendor-agnostic architecture, allowing it to work with your current infrastructure. The platform also supports the deployment of vetted third-party AI solutions and hospital-developed models. The Rapid Mobile App facilitates real-time collaboration and alerts, integrating with EMR for patient case summaries. The platform's infrastructure, Rapid Edge Cloud, provides cloud scalability with on-premise resilience for continuous service.
Details
| Category | Cardiology AI, Neurology AI, Radiology & Imaging AI |
| Pricing | Unknown — unknown |
| Deployment | Hybrid (cloud-first with on-premise capabilities), On-Premise, Cloud |
| Mobile App | Yes |
| API Available | Yes |
| Languages | English |
| Training | Yes |
| Target Size | Hospitals and Health Systems |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Cleared AI-estimated RapidAI has received numerous FDA clearances for its imaging modules, including Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement, which expand its platform for neurology and vascular care. Rapid ASPECTS, an AI neuroimaging analysis product, was approved by the FDA under the CADx product code. Rapid CTP has an FDA indication to aid in the selection of patients for acute stroke therapy. AngioFlow™ by RapidAI, a solution for perfusion imaging analysis directly within the interventional suite, also received 510(k) clearance. The company has approvals in 66 different countries. |
| SOC 2 | Yes AI-estimated |
| GDPR | Yes AI-estimated |
| Integrations | |
| EHR | Allscripts, Athenahealth, Cerner, Epic, Harris Healthcare, MEDITECH |
| Specialties | Cardiology, Critical Care, Emergency Medicine, Neurology, Radiology, Vascular Surgery |
Social Proof
| Customers | 2,500+ |
| Notable | unknown |
Support & Reliability
| Training Provided | Yes |
Ratings & Reviews
Rate Rapid Enterprise Platform
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Rapid Enterprise Platform.
Frequently Asked Questions
Compare Rapid Enterprise Platform
VS
VS
VS
VS
